Literature DB >> 25558402

Phosphoryl guanidines: a new type of nucleic Acid analogues.

M S Kupryushkin1, D V Pyshnyi1, D A Stetsenko1.   

Abstract

A new type of nucleic acid analogues with a phosphoryl guanidine group is described. Oxidation of polymer-supported dinucleoside 2-cyanoethyl phosphite by iodine in the presence of 1,1,3,3-tetramethyl guanidine yields a dinucleotide with an internucleoside tetramethyl phosphoryl guanidine (Tmg) group as the main product. The Tmg group is stable under conditions of solid-phase DNA synthesis and subsequent cleavage and deprotection with ammonia. Oligonucleotides with one or more Tmg groups bind their complementary DNA or RNA with affinity similar to that of natural oligodeoxyribonucleotides.

Entities:  

Keywords:  modified oligonucleotide; nucleic acid analogue; phosphite; phosphoryl guanidine; solid-phase synthesis; tetramethylguanidine

Year:  2014        PMID: 25558402      PMCID: PMC4273099     

Source DB:  PubMed          Journal:  Acta Naturae        ISSN: 2075-8251            Impact factor:   1.845


DISCUSSION

Nucleic acid analogues of various structures are widely used in molecular biology and are regarded as promising therapeutic agents and probes for molecular diagnostics [1, 2]. The main impediment to the widespread application of nucleic acid derivatives for therapy is their generally poor cell uptake in the absence of specific transfection agents or delivery systems. The relative inefficiency of oligonucleotide penetration into cells can be at least partly attributed to their large net negative charge. Only two types of nucleic acid analogues with theoretically charge-neutral backbones have been reasonably well studied over the past 20 years: peptide nucleic acids (PNA) [3] and phosphorodiamidate morpholino oligomers (PMO) [4]. Both types of analogues can bind natural DNA and RNA sequence-specifically and therefore they have found applications both in molecular biology and, in particular, in medicine as potential drugs [5, 6]. Taking this into account, the search for new nucleic acid analogues that could be used for development of oligonucleotide therapeutics capable of efficient cell penetration in the absence of transfection agents or other delivery means remains a highly relevant and challenging task. We have shown that oxidation of 3’,5’-dithymidine- β-cyanoethyl phosphite by iodine in pyridine in the presence of 1,1,3,3-tetramethyl guanidine (TMG) yields a dinucleotide with an internucleotide tetramethyl phosphoryl guanidine group (Tmg) as the main product (Figure A) (similarly, oxidation of trialkylphosphite with iodine in pyridine in the presence of a primary amine yields phosphoramidates [7]). Solid-phase oligonucleotide synthesis was carried out until hexathymidylate was formed. The oligonucleotide was cleaved from the polymer using a 25% aqueous ammonia solution at room temperature for 1 h; ammonia was subsequently removed in vacuo, and the solution containing the oligonucleotide was analyzed by RP-HPLC and MALDI-TOF mass spectrometry. A – Structure of an oligonucleotide with an internucleotide tetramethyl phosphoryl guanidine group (Tmg). B – Elution profile of an oligonucleotide 5'-d(T5p*T), where p* indicates the position of the Tmg group. RP-HPLC was carried out on an Agilent 1200 HPLC system (USA) using a Zorbax SB-C18 (5 um) 4.6 × 150 mm column with a gradient of acetonitrile (0 → 40%) in 20 mM triethylammonium acetate (pH 7) for 30 min; flow rate 2 mL/min The elution profile of the reaction mixture (Figure B) showed that the main product is an oligonucleotide 5'-d(T5p*T), where p* indicates the position of the Tmg group. Two main peaks with τR 16.7 and 17.6 min corresponded to the modified oligonucleotides; they were assigned to individual diastereomers resulting from chirality of the internucleotide phosphoryl guanidine group. The unmodified oligonucleotide dT6 ( τR 14.3) was also present as a by-product that most likely was formed via hydrolysis of the intermediate reactive iodophosphonium derivative by traces of moisture. The Tmg group exhibits pronounced hydrophobic properties: it is characterized by a longer retention time (τR) of the Tmg group-containing oligonucleotides compared with that of the unmodified oligonucleotide. Other modified oligothymidylates up to 20 nucleotide long have been synthesized, featuring one or two Tmg groups at various positions in the oligonucleotide chain. The presence of tetramethyl phosphoryl guanidine groups in the oligonucleotides was confirmed by MALDI- TOF mass spectrometry (Table). Structures and molecular masses of phosphoryl guanidine oligonucleotide derivatives with the Tmg group p* indicates the position of the Tmg group. #Positive or negative ion MALDI-TOF spectra were recorded on a Bruker Reflex III Autoflex Speed mass spectrometer (Germany) using 3-hydroxypicolinic acid as a matrix. Thermal denaturation experiments with optical registration of signal carried out at 10-5 M concentrations of each oligonucleotide in a 10 mM Na-cacodylate buffer (pH 7.2) containing 100 mM NaCl and 5 mM MgCl2 showed a relatively small effect of an isolated Tmg group at the 3’-end or in the middle of the chain on the stability of the complementary complex formed by the modified oligodeoxyribonucleotides with poly(dA) or poly(rA) templates as compared with the unmodified oligonucleotide dT20. The melting temperatures (Tm) for the complexes formed with a poly(rA) template were 48°C for 5'-d(T19p*T) and 46.5°C for 5'-d(T11p*T9); for those formed with a poly(dA) template, the Tms were 54 and 52.5°C, respectively, which was sufficiently close to the Tm of the complexes formed by the unmodified dT20 oligonucleotide with the same templates (48 and 55°C, respectively). Individual d(T19p*T) diastereomers, which could be separated by RP-HPLC, showed only slightly different Tm values with the dC2A20C2 template: 45.8°C for the diastereomer with a shorter retention time and 45.1oC for the diastereomer with a longer retention time, compared with 45.1°C for the unmodified dT20 oligonucleotide. The complex of an oligonucleotide d(T11p*T9) with the modification in the middle of the chain, obtained as a mixture of diastereomers, melted at 44.7°C. These results are quite surprising, since a replacement of an internucleotide phosphate with the tetramethyl phosphoryl guanidine group leads to the substitution of a 20-atom group (including hydrogens) for one oxygen atom. The data indicated that oligodeoxyribonucleotides modified with Tmg groups can bind their complementary DNA and RNA to form stable complexes that differ only slightly in their thermal stability from the natural duplexes, a property which is a prerequisite for their therapeutic application. To conclude, we have described a new type of nucleic acid analogues, phosphoryl guanidines [8], which is a third class of the formally charge-neutral oligonucleotide derivatives described so far in addition to known peptide nucleic acids (PNA) and morpholino oligomers (PMO). Our results indicate that oxidation of an internucleotide phosphite triester by iodine in pyridine in the presence of 1,1,3,3-tetramethylguanidine is a convenient method for obtaining oligonucleotide derivatives with the tetramethyl phosphoryl guanidine (Tmg) group. It is noteworthy that, unlike the previously described oligonucleotide analogues such as PNA or PMO, phosphoryl guanidine derivatives can be synthesized by conventional phosphoramidite chemistry using a standard DNA synthesizer. Therefore, it becomes possible to obtain various phosphoryl guanidine oligomers using a wide range of commercially available phosphoramidites, including those modified at the sugar residue and/or heterocyclic base. We have shown that the Tmg group is stable under solid-phase oligonucleotide synthesis conditions, subsequent deprotection and cleavage from their polymer support of mixed-sequence oligodeoxyribonucleotides using standard 25% aqueous ammonia treatment at 55°C for 16 h. Oligonucleotides containing one or more Tmg groups are able to bind their complementary DNA and RNA sequences with affinity that is only slightly different from that of natural oligodeoxyribonucleotides, despite the steric bulk of the Tmg group. In our opinion, the results obtained indicate that this novel class of phosphoryl guanidine nucleic acid analogues may be quite promising for the designing of new biologically active oligonucleotide derivatives.
Table

Structures and molecular masses of phosphoryl guanidine oligonucleotide derivatives with the Tmg group

Oligonucleotide sequence, 5' → 3' Molecular mass#
Calculated [M] Experimental
[M + H]+[M - H]-
1d(TTTTTp*T)1860.391860.351857.54
2d(Tp*TTTTT)1860.391860.341858.63
3d(TCp*A)941.80942.17938.97
4d(TTTTTTTTTTTTTTTTTTTp*T)6119.166121.136113.80
5d(TTTTTTTTTTTp*TTTTTTTTT)6119.166121.54-
6d(TTp*TTTTTTTTTTTTTTTTTT)6119.166120.016114.19
7d(TTp*TTTTTTTTTTTTTTTTTp*T)6216.33-6221.11

p* indicates the position of the Tmg group.

#Positive or negative ion MALDI-TOF spectra were recorded on a Bruker Reflex III Autoflex Speed mass spectrometer (Germany) using 3-hydroxypicolinic acid as a matrix.

  5 in total

Review 1.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

Review 2.  Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino.

Authors:  Shantanu Karkare; Deepak Bhatnagar
Journal:  Appl Microbiol Biotechnol       Date:  2006-05-09       Impact factor: 4.813

Review 3.  Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications.

Authors:  Neil M Bell; Jason Micklefield
Journal:  Chembiochem       Date:  2009-11-23       Impact factor: 3.164

Review 4.  Morpholino antisense oligomers: design, preparation, and properties.

Authors:  J Summerton; D Weller
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-06

5.  Oligonucleotide N-alkylphosphoramidates: synthesis and binding to polynucleotides.

Authors:  A Jäger; M J Levy; S M Hecht
Journal:  Biochemistry       Date:  1988-09-20       Impact factor: 3.162

  5 in total
  8 in total

1.  Oligonucleotide therapies for disorders of the nervous system.

Authors:  Olga Khorkova; Claes Wahlestedt
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

2.  Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides.

Authors:  Prashant Monian; Chikdu Shivalila; Genliang Lu; Mamoru Shimizu; David Boulay; Karley Bussow; Michael Byrne; Adam Bezigian; Arindom Chatterjee; David Chew; Jigar Desai; Frank Favaloro; Jack Godfrey; Andrew Hoss; Naoki Iwamoto; Tomomi Kawamoto; Jayakanthan Kumarasamy; Anthony Lamattina; Amber Lindsey; Fangjun Liu; Richard Looby; Subramanian Marappan; Jake Metterville; Ronelle Murphy; Jeff Rossi; Tom Pu; Bijay Bhattarai; Stephany Standley; Snehlata Tripathi; Hailin Yang; Yuan Yin; Hui Yu; Cong Zhou; Luciano H Apponi; Pachamuthu Kandasamy; Chandra Vargeese
Journal:  Nat Biotechnol       Date:  2022-03-07       Impact factor: 68.164

3.  Data for isolation and properties analysis of diastereomers of a mono-substituted phosphoryl guanidine trideoxyribonucleotide.

Authors:  Alexander A Lomzov; Maxim S Kupryushkin; Andrey V Shernyukov; Mikhail D Nekrasov; Ilya S Dovydenko; Dmitry A Stetsenko; Dmitrii V Pyshnyi
Journal:  Data Brief       Date:  2019-06-20

4.  A New Antisense Phosphoryl Guanidine Oligo-2'-O-Methylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression.

Authors:  Yulia V Skvortsova; Elena G Salina; Ekaterina A Burakova; Oksana S Bychenko; Dmitry A Stetsenko; Tatyana L Azhikina
Journal:  Front Pharmacol       Date:  2019-09-19       Impact factor: 5.810

5.  Antisense oligonucleotide gapmers containing phosphoryl guanidine groups reverse MDR1-mediated multiple drug resistance of tumor cells.

Authors:  Maxim S Kupryushkin; Anton V Filatov; Nadezhda L Mironova; Olga A Patutina; Ivan V Chernikov; Elena L Chernolovskaya; Marina A Zenkova; Dmitrii V Pyshnyi; Dmitry A Stetsenko; Sidney Altman; Valentin V Vlassov
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-29       Impact factor: 8.886

Review 6.  Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.

Authors:  Jacob Helm; Ludger Schöls; Stefan Hauser
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

7.  Transport Oligonucleotides-A Novel System for Intracellular Delivery of Antisense Therapeutics.

Authors:  Oleg V Markov; Anton V Filatov; Maxim S Kupryushkin; Ivan V Chernikov; Olga A Patutina; Anton A Strunov; Elena L Chernolovskaya; Valentin V Vlassov; Dmitrii V Pyshnyi; Marina A Zenkova
Journal:  Molecules       Date:  2020-08-11       Impact factor: 4.411

8.  Control of backbone chemistry and chirality boost oligonucleotide splice switching activity.

Authors:  Pachamuthu Kandasamy; Graham McClorey; Mamoru Shimizu; Nayantara Kothari; Rowshon Alam; Naoki Iwamoto; Jayakanthan Kumarasamy; Gopal R Bommineni; Adam Bezigian; Onanong Chivatakarn; David C D Butler; Michael Byrne; Katarzyna Chwalenia; Kay E Davies; Jigar Desai; Juili Dilip Shelke; Ann F Durbin; Ruth Ellerington; Ben Edwards; Jack Godfrey; Andrew Hoss; Fangjun Liu; Kenneth Longo; Genliang Lu; Subramanian Marappan; Jacopo Oieni; Ik-Hyeon Paik; Erin Purcell Estabrook; Chikdu Shivalila; Maeve Tischbein; Tomomi Kawamoto; Carlo Rinaldi; Joana Rajão-Saraiva; Snehlata Tripathi; Hailin Yang; Yuan Yin; Xiansi Zhao; Cong Zhou; Jason Zhang; Luciano Apponi; Matthew J A Wood; Chandra Vargeese
Journal:  Nucleic Acids Res       Date:  2022-06-10       Impact factor: 19.160

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.